Standard Confidentiality Disclosure Agreement for Clinical Trial Preamble WHEREAS this Standard Confidentiality Disclosure Agreement was approved by the Danish Regions on May 1, 2012 as version 1; WHEREAS this Standard Confidentiality Disclosure Agreement shall be used when initiating discussions between two parties, one being the Sponsor of a potential clinical study, the other being a public institution in Denmark; WHEREAS the purpose of using this Standard Confidentiality Disclosure Agreement is to enable the Parties to enter into an agreement under standardised legal terms; WHEREAS the main body of this Standard Confidentiality Agreement may not be changed; WHEREAS the Parties on a project by project basis agree on the specific definition of the Information to be disclosed under this Standard Confidentiality Disclosure Agreement, and define this in detail using Appendix A and sign the complete Standard Confidentiality Disclosure Agreement using Appendix B; WHEREAS, the Discloser, as defined below, has developed and possesses certain proprietary information relating to clinical trial development; WHEREAS, the Recipient, as defined below, desires to obtain access to such Information for the purpose of evaluating its interest in engaging in conducting a clinical study; WHEREAS, Discloser is willing to disclose to the Recipient said Information for evaluation and determination of the Recipient’s interest therein; NOW, THEREFORE the Discloser and the Recipient (also individually referred to as a and collectively as the Parties) hereto agree as follows: 1. Confidentiality 1.1 In the course of the discussions Recipient may receive or obtain from Discloser certain trade secrets, confidential scientific, technical or commercial information or data (either its own or that of its business partners) relating to Disclosers Study Project as defined in Appendix A (the “Information”), designated as confidential in writing by Discloser, whether by letter or by use of an appropriate proprietary stamp or legend, prior to or at the time of any such Information being disclosed by the Discloser to the Recipient. Notwithstanding the foregoing, information which is orally or visually disclosed to Recipient by Discloser, or is disclosed in writing without an appropriate letter, proprietary stamp or legend, shall constitute Information if Discloser, within thirty (30) days after such disclosure,
Standard Confidentiality Disclosure Agreement for Clinical Trial Preamble WHEREAS this Standard Confidentiality Disclosure Agreement was approved by the Danish Regions on May 1, 2012 as version 1; WHEREAS this Standard Confidentiality Disclosure Agreement shall be used when initiating discussions between two parties, one being the Sponsor of a potential clinical study, the other being a public institution in Denmark; WHEREAS the purpose of using this Standard Confidentiality Disclosure Agreement is to enable the Parties to enter into an agreement under standardised legal terms; WHEREAS the main body of this Standard Confidentiality Agreement may not be changed; WHEREAS the Parties on a project by project basis agree on the specific definition of the Information to be disclosed under this Standard Confidentiality Disclosure Agreement, and define this in detail using Appendix A and sign the complete Standard Confidentiality Disclosure Agreement using Appendix B; WHEREAS, the Discloser, as defined below, has developed and possesses certain proprietary information relating to clinical trial development; WHEREAS, the Recipient, as defined below, desires to obtain access to such Information for the purpose of evaluating its interest in engaging in conducting a clinical study; WHEREAS, Discloser is willing to disclose to the Recipient said Information for evaluation and determination of the Recipient’s interest therein; NOW, THEREFORE the Discloser and the Recipient (also individually referred to as a and collectively as the Parties) hereto agree as follows: 1. Confidentiality 1.1 In the course of the discussions Recipient may receive or obtain from Discloser certain trade secrets, confidential scientific, technical or commercial information or data (either its own or that of its business partners) relating to Disclosers Study Project as defined in Appendix A (the “Information”), designated as confidential in writing by Discloser, whether by letter or by use of an appropriate proprietary stamp or legend, prior to or at the time of any such Information being disclosed by the Discloser to the Recipient. Notwithstanding the foregoing, information which is orally or visually disclosed to Recipient by Discloser, or is disclosed in writing without an appropriate letter, proprietary stamp or legend, shall constitute Information if Discloser, within thirty (30) days after such disclosure,
Standard_Confidentiality_Disclosure_Agreement_for_Clinical_Trial_May_2012.docx